PMID- 23725283
OWN - NLM
STAT- MEDLINE
DCOM- 20140113
LR  - 20130603
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 5
IP  - 6
DP  - 2013 Jun
TI  - The potential role of dendritic cells in the therapy of Type 1 diabetes.
PG  - 591-606
LID - 10.2217/imt.13.48 [doi]
AB  - Type 1 diabetes (T1D) is the result of T-cell mediated autoimmune destruction of 
      pancreatic islet beta-cells. The two current treatments for T1D are based on insulin 
      or islet-cell replacement rather than the pathogenesis of T1D and remain 
      problematic. Islet/pancreas transplantation does not cater for the majority of 
      sufferers due to the lack of supply of organs and the need for continuous 
      immunosuppression regimens. The mainstay treatment is insulin replacement, but 
      this is disruptive to lifestyle and does not protect against severe long-term 
      complications. An early vaccination and long-term restoration of immune tolerance 
      to self-antigens in T1D patients (reversing the immunopathogenesis of the 
      disease) would be preferable. Dendritic cells (DCs) are potent APCs and play an 
      important role in inducing and maintaining immune tolerance. Targeting DCs 
      through different DC surface molecules shows effective modulation of immune 
      responses. Their feasibility for immunotherapy to prolong transplant survival and 
      cancer immunotherapy has been demonstrated. Therefore, DCs could potentially be 
      used in the treatment of autoimmune diseases. This review summarizes new insights 
      into DCs as a potential therapeutic target for the treatment of T1D.
FAU - Lee, Chin-Nien
AU  - Lee CN
AD  - Molecular Immunology Division, The Walter & Eliza Hall Institute of Medical 
      Research, Parkville, VIC 3052, Australia.
FAU - Lew, Andrew M
AU  - Lew AM
FAU - Wu, Li
AU  - Wu L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - Dendritic Cells/*immunology
MH  - Diabetes Mellitus, Type 1/*immunology/*therapy
MH  - Humans
MH  - *Immune Tolerance
MH  - Immunotherapy/*methods
MH  - T-Lymphocytes/immunology
EDAT- 2013/06/04 06:00
MHDA- 2014/01/15 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/06/04 06:00 [entrez]
PHST- 2013/06/04 06:00 [pubmed]
PHST- 2014/01/15 06:00 [medline]
AID - 10.2217/imt.13.48 [doi]
PST - ppublish
SO  - Immunotherapy. 2013 Jun;5(6):591-606. doi: 10.2217/imt.13.48.